Overview

Repositioning Immunotherapy in VetArans With Lung Cancer

Status:
RECRUITING
Trial end date:
2030-03-31
Target enrollment:
Participant gender:
Summary
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
Phase:
PHASE2
Details
Lead Sponsor:
VA Office of Research and Development
Treatments:
Nivolumab